Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clinical Data
Biotech
Despite ph. 3 miss, Alkeus sees path forward for eye disease med
Despite a phase 3 miss, Alkeus still sees a path forward for its oral eye disease asset.
Gabrielle Masson
Sep 17, 2024 10:58am
Ascendis' dwarfism drug hits in phase 3, threatens BioMarin
Sep 17, 2024 9:36am
Merck, Daiichi ADC hits goal in phase 3 lung cancer study
Sep 17, 2024 7:13am
ESMO: Lantheus' radiotherapy readout not enough to best Pluvicto
Sep 16, 2024 8:55am
Boehringer's phase 3 lung fibrosis trial hits primary endpoint
Sep 16, 2024 8:30am
ESMO: Bristol Myers axes Immatics' bispecific after $150M bet
Sep 16, 2024 6:59am
